Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: The effect of Nrf2 deletion on the proteomic signature in a human colorectal cancer cell line

Fig. 1

Investigating the fold change expression of (A) Nrf2 and (B) HMOX-I in HT29 and HT29-Nrf2− cell line. C Western blot data of Nrf2 downstream HO-1 gene (D) Nrf2 related enzyme assay showed a reduction in antioxidant enzymes activity accompanied by an increase in prooxidant markers such as MDA and H2O2. Cytotoxicity effects of (E) Doxorubicin and (F) Cisplatin treatment on HT29 and HT29-Nrf2− cell line, exhibiting a dose- and time-dependent manner. G, H, I In-vitro scratch assay to investigate the effect of Doxorubicin and Cisplatin chemotherapy drugs on migration of HT29 cells after 24 and 48 hours treatment. The cells were treated with 125 μM concentration of Cisplatin (for 24 and 48 hours) and 0.6 μM concentration of Doxorubicin drugs (for 24 hours). The HT29-Nrf2− cells were more susceptible to drug treatment. Results were expressed as the mean ± SD (*p < 0.05, **p < 0.01, and ***p < 0.001)

Back to article page